ANNUAL GENERAL MEETING

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)
(the "**Company**")

REMINDER NOTICE OF ANNUAL GENERAL MEETING FOR FY2025

IMPORTANT NOTE FOR S-SHARE SHAREHOLDERS

The Company had previously issued a notice of the Annual General Meeting on 30 March 2026 in compliance with Article 69 of its Articles of Association and the listing rules of the Shanghai Stock Exchange, which require a written notice to be given at least 45 days in advance of a shareholders' meeting. Subsequently, on 16 April 2026, the Company issued a further notice in compliance with the requirements of the Shanghai Stock Exchange to notify S-Share Shareholders that the controlling shareholder of the Company had proposed one (1) *ad hoc* resolution (临时提案) (i.e. Resolution 16) for inclusion in the agenda of the Annual General Meeting, and such further notice superseded the notice dated 30 March 2026.

On 30 April 2026, the Company announced an updated notice of the Annual General Meeting. This updated notice, issued in compliance with the listing rules of the Singapore Exchange Securities Trading Limited, supersedes the notice announced by the Company on 16 April 2026.

The Board refers to the notice of the annual general meeting for FY2025 (as defined below) released by the Company on 30 April 2026. Pursuant to the Articles of Association of the Company, the Board hereby issues this reminder notice of the annual general meeting for FY2025.

REMINDER NOTICE IS HEREBY GIVEN that the annual general meeting of the Company (the "**AGM**" or "**Annual General Meeting**") for the financial year ended 31 December 2025 ("**FY2025**") will be held at the meeting room of the Company's Modern Traditional Chinese Medicine Industrial Park located at No. 21 Tenth Avenue, Binhai New Area, Tianjin, the People's Republic of China (the "**PRC**") (中国天津市滨海新区第十大街21号津药达仁堂集团现代中药产业园会议室) (concurrently, via video conferencing at Meeting Room 2&3, 126 Beach Road, Guoco Midtown Network Hub Level 2, Singapore 189772 for holders of S-Shares (the "**S-Share Shareholders**") in Singapore) on Friday, 15 May 2026 at 1:30 p.m..

The agenda for the meeting shall be as follows:

RESOLUTION(S) (POLL VOTING) (*See Explanatory Note F*)

1. To consider and approve the Chairman's Report for FY2025. **(Resolution 1)**

2. To consider and approve the Board of Directors' Report for FY2025. **(Resolution 2)**

3. To consider and approve the Financial Report and Audit Report for FY2025, which have been audited by CAC Certified Public Accountants LLP (中审华会计师事务所) and Foo Kon Tan LLP, and reviewed by the Audit Committee of the Company. **(Resolution 3)**

4. To consider and approve the profit distribution plan of the Company for FY2025. **(Resolution 4)**

The Board proposes to declare a final dividend for FY2025 on the basis of RMB23.4 (inclusive of taxes) for every ten (10) shares in the capital of the Company (the "**Proposed Final Dividend**"). Subject to the Proposed Final Dividend being approved by shareholders at the Annual General Meeting, the Proposed Final Dividend will be paid in respect of all issued shares in the capital of the Company as at the record date to be determined by the Company for the purposes of determining shareholders' entitlements to the Proposed Final Dividend. The Company will announce the record date and the payment date for the Proposed Final Dividend in due course.

5. To consider and approve the remuneration of S$55,000 for Independent Director Mr. Yeo Guat Kwang (杨木光) for FY2025. **(Resolution 5)**

6. To consider and approve the remuneration of S$55,000 for Independent Director Mr. Liew Yoke Pheng Joseph (刘育彬) for FY2025. **(Resolution 6)**

7. To consider and approve the remuneration of S$55,000 for Independent Director Mr. Zhong Ming (钟铭) for FY2025. **(Resolution 7)**

8. To consider and approve the aggregate remuneration for the Directors of the Company for FY2025. **(Resolution 8)**

9. To consider and approve the proposed renewal of the shareholders' mandate for interested person transactions: **(Resolution 9)**

   (a) such approval given in the shareholders' mandate for interested person transactions (the "**Shareholders' Mandate**") shall, unless revoked or varied by the Company at a general meeting, continue in force until the next annual general meeting of the Company; and

   (b) the Directors and/or any of them are hereby authorised to complete and do all such acts and things (including executing all such documents as may be required) as they and/or he/she may consider expedient or necessary or in the interests of the Company to give effect to the transactions contemplated and/or authorised by the Shareholders' Mandate and/or this Resolution.

   (See Explanatory Note A)

10. To consider and approve the proposed Company's "Shareholders' Return Plan for 2026 to 2028". **(Resolution 10)**

    (See Explanatory Note B)

11. To consider and approve the proposed lines of credit granted to the Company up to an aggregate limit of RMB13,455 million. **(Resolution 11)**

    (See Explanatory Note C)

12. To consider and approve the proposed entry into the financial services agreement between the Company and Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司) ("**TPGF**") as an interested person transaction and all transactions arising therefrom. **(Resolution 12)**

(See Explanatory Note D)

13. To consider and approve the proposed provision by the Company, in proportion to its equity interest in Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) ("**Taiping Medicine**"), of a guarantee of up to RMB1,408,875,000 in respect of credit facilities to be obtained by Taiping Medicine from third-party financial institutions as an interested person transaction. **(Resolution 13)**

(See Explanatory Note D)

14. To consider and approve the proposed provision by the Company, in proportion to its indirect equity interest in Tianjin Zhongxin Medicine Co., Ltd. (天津中新医药有限公司) ("**TJZX Medicine**") (through Taiping Medicine), of a guarantee of up to RMB1,257,150,000 in respect of credit facilities to be obtained by TJZX Medicine from third-party financial institutions as an interested person transaction. **(Resolution 14)**

(See Explanatory Note D)

15. To consider and approve the proposed provision by the Company, in proportion to its indirect equity interest in TJZX Medicine (through Taiping Medicine), of a guarantee of up to RMB433,500,000 in respect of credit facilities to be obtained by TJZX Medicine from TPGF as an interested person transaction. **(Resolution 15)**

(See Explanatory Note D)

Other items on the agenda to be resolved in the Annual General Meeting shall include any agenda proposed by a Shareholder in accordance with Article 70 of the Articles of Association of the Company, which states: *"When the Company is to hold an annual General Meeting, shareholders holding three per cent. (3%) or more of the voting shares of the Company shall be entitled to propose new motions in writing to the Company. The Company shall include in the agenda of the General Meeting those motions, the subject matter of which, are required to be decided by shareholders in General Meeting*".

RESOLUTION(S) (CUMULATIVE VOTING) (*See Explanatory Note G*)

To consider and approve the proposed appointment of one (1) Independent Director of the Company:

16. To consider and approve the proposed appointment of Ms. Zhai Shuping (翟淑萍) as an Independent Director of the Company. **(Resolution 16)**

(See Explanatory Note E)

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
11 May 2026

Explanatory Notes:

A. **Resolution 9** is to renew the Shareholders' Mandate to enable the Company, its subsidiaries and associated companies that are considered to be "entities at risk" within the meaning of Chapter 9 of the Listing Manual of the Singapore Exchange Securities Trading Limited (the "**Listing Manual**"), or any of them, to enter into certain categories of interested person transactions with certain classes of interested persons. Further details are set out in the annexure dated 30 April 2026 to this Notice of AGM in relation to the proposed renewal of the shareholders' mandate for interested person transactions (the "**IPT Mandate Annexure**"), as set out on pages 176 to 201 of the Company's annual report for FY2025 (the "**Annual Report 2025**").

B. **Resolution 10** is to seek the approval of the shareholders of the Company (the "**Shareholders**") for the Company's Shareholders' Return Plan for the next three (3) years from 2026 to 2028. Further details are set out in the Company's announcement dated 30 March 2026 in relation to the Shareholders' Return Plan for 2026 to 2028.

C. **Resolution 11** is to seek Shareholders' approval for the proposed lines of credit granted to the Company up to an aggregate limit of RMB13,455 million, and to authorise the Company's management, based on the Company's operational needs, to handle the relevant matters relating to loans and other financing arrangements under such lines of credit. Further details of the proposed lines of credit are set out in the Company's announcement dated 30 March 2026 in relation to, *inter alia*, the resolutions passed at the 2nd Board meeting for the financial year ending 31 December 2026.

D. **Resolutions 12, 13, 14 and 15** are to seek Shareholders' approval for the proposed interested person transactions (the "**Proposed IPTs**"). Further details are set out in the annexure dated 30 April 2026 to this Notice of AGM in relation to the Proposed IPTs (the "**Proposed IPTs Annexure**"), released together with this Notice of AGM.

E. **Resolution 16** is to appoint Ms. Zhai ShuPing (翟淑萍) as an Independent Director of the Company. Further details of Ms. Zhai ShuPing (翟淑萍), including the information required under Rule 720(6) of the Listing Manual read with Appendix 7.4.1 of the Listing Manual, are set out in the section entitled "Corporate Governance Statement" in the Company's Annual Report 2025.

F. Resolutions 1 to 15 will be voted on **BY WAY OF POLL**, and every Shareholder shall be entitled to one (1) vote for every Share such Shareholder holds or such proxy represents.

G. Resolution 16 pertaining to the proposed appointment of Ms. Zhai ShuPing (翟淑萍) as an Independent Director of the Company will be voted on **BY WAY OF CUMULATIVE VOTING**, in one (1) proposal group. Every Shareholder (including S-Share Shareholder) shall, in respect of the resolution(s) under such proposal group, be entitled to a number of votes equivalent to the number of Shares such Shareholder (including S-Share Shareholder) holds or such proxy represents multiplied by the number of the candidate(s) standing for election as director under that proposal group, and the Shareholders (including S-Share Shareholders) may cast all or part of their votes for one (1) or several candidates standing for election as director under that proposal group.

IMPORTANT - Cumulative Voting for Election of Director(s)

(a) Resolution 16 will be voted on by way of cumulative voting in one (1) proposal group, and every Shareholder (including S-Share Shareholder) shall, in respect of Resolution 16 under such proposal group, be entitled to a number of votes equivalent to the number of Shares such Shareholder (including S-Share Shareholder) holds or such proxy represents multiplied by the number of the candidate(s) standing for election as director under such proposal group. **Please <u>DO NOT</u> indicate with a tick (✓) or a cross (✗) within the box provided in respect of Resolution 16 in the proxy form in respect of the AGM (the "Proxy Form"). <u>Instead, you should indicate the number of votes as appropriate</u>. Please see the detailed illustration as set out below.**

(b) The cumulative voting will be conducted in one (1) proposal group, categorised into resolution(s) for the election of independent director(s). This means that for the election of the one (1) independent director, the total number of votes you are entitled to cast in aggregate for Resolution 16 shall equal the number of Shares held by you multiplied by the number of the candidate(s) standing for election as independent director(s) under such proposal group in relation to the proposed appointment of independent director(s) of the Company (i.e. 1), and this particular allocation of votes may only be cast on the candidate(s) standing for election as independent director under such proposal group.

As to the allocation of votes within the relevant proposal group, you may either cast all your relevant number of votes for that proposal group for one (1) of the candidate(s) in that proposal group, or where applicable, cast them equally or diversely to more than one (1) of the candidate(s) (as the case may be) in that proposal group.

<u>PLEASE NOTE WITH PARTICULAR ATTENTION THAT, IF THE TOTAL NUMBER OF VOTES YOU HAVE CAST IS LESS THAN OR EQUAL TO THE MAXIMUM NUMBER OF VOTES YOU ARE ENTITLED TO CAST IN RESPECT OF THAT PARTICULAR PROPOSAL GROUP, YOUR VOTES SHALL BE VALID AND THE VOTES NOT CAST SHALL BE DEEMED TO HAVE BEEN WAIVED BY YOU; IF THE TOTAL NUMBER OF VOTES YOU HAVE CAST EXCEEDS THE MAXIMUM NUMBER OF VOTES YOU ARE ENTITLED TO CAST IN RESPECT OF THAT PARTICULAR PROPOSAL GROUP, ALL THE VOTES CAST BY YOU SHALL BE INVALID AND YOU SHALL BE DEEMED TO HAVE WAIVED YOUR RIGHT TO VOTE.</u>

Solely for illustrative purposes only:

If you hold **100 Shares**, as there is one (1) candidate standing for election as independent director under the proposal group in relation to the proposed appointment of independent director(s) of the Company (i.e. Resolution 16), the total number of votes you are entitled to cast under this proposal group will be **100 votes**, and these 100 votes may only be cast on the proposed candidate standing for election as independent director under the proposal group in relation to the proposed appointment of independent director(s) of the Company. You may cast all the **100 votes** or only part of them that you are entitled to cast under the proposal group in relation to the proposed appointment of independent director(s) of the Company.

(c) A candidate standing for election as director shall be determined as elected according to the number of votes received by each candidate in descending order; provided, however, that for a candidate to be elected, the minimum number of votes that such candidate received shall be more than half (1/2) of the total number of Shares held by those Shareholders attending the general meeting. If none of the candidates received votes that are more than half (1/2) of the total number of Shares held by those Shareholders attending the general meeting, none of the candidates will be elected at the general meeting and another election shall be conducted at the next following general meeting to fill the vacancy.

If the number of directors successfully elected is less than the number of directors to be elected at the general meeting, another election shall be conducted at the next following general meeting to fill the vacancy.

If the number of the candidates standing for election as director who have received more than half (1/2) of the total number of Shares held by those Shareholders attending the general meeting is more than the number of directors to be elected at the general meeting, the candidates standing for election as director shall be determined as elected according to the number of votes received by each candidate in descending order.

In the event of failure to determine the elected candidate due to a tie vote between two (2) or more candidates standing for election as director (such that, if all of them are elected, the number of elected candidates would exceed the number of vacancies), none of these candidates will be elected at the general meeting and another election shall be conducted at the next following general meeting to fill the vacancy.

Notes:

1. The AGM will be held at the meeting room of the Company's Modern Traditional Chinese Medicine Industrial Park located at No. 21 Tenth Avenue, Binhai New Area, Tianjin, the PRC (中国天津市滨海新区第十大街 21 号津药达仁堂集团现代中药产业园会议室) (concurrently, via video conferencing at Meeting Room 2&3, 126 Beach Road, Guoco Midtown Network Hub Level 2, Singapore 189772 for S-Share Shareholders in Singapore) on Friday, 15 May 2026 at 1:30 p.m..

2. AGM documents. Printed copies of the Company's Annual Report 2025 enclosing, *inter alia*, the IPT Mandate Annexure (which includes printed copies of this Notice of AGM and the Proxy Form), as well as printed copies of the Proposed IPTs Annexure, have been sent to S-Share Shareholders. The Annual Report 2025, this Notice of AGM, the Proxy Form, and the Proposed IPTs Annexure have also been made available via SGXNet and on the Company's website at www.jydrt.com.cn. S-Share Shareholders and investors are advised to check SGXNet and/or the Company's website at www.jydrt.com.cn regularly for the latest updates.

3. Shareholders' questions and answers. S-Share Shareholders and duly appointed proxy or proxies will be able to attend the AGM in person and ask questions relating to the resolutions to be tabled for approval at the AGM.

   However, S-Share Shareholders are encouraged to raise their questions (if any) as early as possible in advance of the AGM and, in any event, by **5:00 p.m.** on **Monday**, **11 May 2026** (being not less than seven (7) calendar days after the date of the Notice of AGM) and can submit substantial and relevant questions relating to the resolutions to be tabled for approval at the AGM, in advance of the AGM, in the following manner:

   (a) by email to drt600329@163.com; or

   (b) by post to the Company's S-Shares Registrar and Singapore Transfer Office, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, Keppel Bay Tower #14-07, Singapore 098632.

   S-Share Shareholders who submit questions in advance of the AGM should provide their full name, address, contact number, email address and the manner in which they hold Shares (if you hold Shares directly, please provide your account number with The Central Depository (Pte) Limited; otherwise, please state if you hold your Shares through the Central Provident Fund Investment Scheme ("**CPF**") or the Supplementary Retirement Scheme ("**SRS**") or other Relevant Intermediary), for our verification purposes. "**Relevant Intermediary**" means (a) a banking corporation licensed under the Banking Act 1970 of Singapore or a wholly-owned subsidiary of such a banking corporation, whose business includes the provision of nominee services and who holds shares in that capacity; (b) a person holding a capital markets services

licence to provide custodial services for securities under the Securities and Futures Act 2001 of Singapore and who holds shares in that capacity; or (c) the CPF Board established by the Central Provident Fund Act 1953 of Singapore, in respect of shares purchased under the subsidiary legislation made under that Act providing for the making of investments from the contributions and interest standing to the credit of members of the CPF, if the Board holds those shares in the capacity of an intermediary pursuant to or in accordance with that subsidiary legislation.

The Company will endeavour to answer all substantial and relevant questions in relation to the resolutions to be tabled for approval at the AGM either prior to or at the AGM. **Where substantially similar questions are received, the Company may consolidate such questions and consequently not all questions may be individually addressed.**

The Company will also publish the minutes of the AGM, which will include substantial and relevant questions relating to the resolutions to be tabled for approval at the AGM and the responses from the Board and/or management of the Company to such questions, via SGXNet and on the Company's website at www.jydrt.com.cn within one (1) month after the date of the AGM.

4. Voting. A Shareholder (whether individual or corporate, including Relevant Intermediaries) who is entitled to attend and vote at the AGM may appoint one (1) or more persons (who need not also be Shareholder(s)) to act as his/her/its proxy(ies) to attend and vote on his/her/its behalf at the AGM. Where a Shareholder appoints more than one (1) proxy, the appointments shall be deemed to be in the alternative unless he/she/it specifies the proportion of his/her/its shareholding (expressed as a percentage of the whole) to be represented by each proxy.

If the appointor is a corporation, the instrument of proxy must be executed under seal or by the hand of its duly authorised officer or attorney.

A S-Share Shareholder (whether individual or corporate) can also choose to appoint the Chairman of the AGM as his/her/its proxy, but this is not mandatory. The Chairman of the AGM, as proxy, need not be a Shareholder of the Company. Where a S-Share Shareholder (whether individual or corporate) appoints the Chairman of the AGM as his/her/its proxy:

(a) in respect of Resolutions 1 to 15, he/she/it must give specific instructions as to voting, or abstentions from voting, in the Proxy Form. **In the absence of specific instructions, the appointment of the Chairman of the AGM as his/her/its proxy for that resolution will be treated as invalid**; and

(b) in respect of Resolution 16, for which cumulative voting will apply, he/she/it must give specific instructions as to how many votes he/she/it wishes to cast on Resolution 16, in the Proxy Form**. If no specific direction as to how many votes is given, the appointment of the Chairman of the AGM as his/her/its proxy for Resolution 16 will be treated as invalid.**

Where a S-Share Shareholder (whether individual or corporate) appoints one (1) or more persons (other than the Chairman of the AGM) as his/her/its proxy(ies):

(a) in respect of Resolutions 1 to 15, he/she/it must give specific instructions as to voting, or abstentions from voting, in the Proxy Form. **In the absence of specific instructions, the proxy(ies) may vote or abstain from voting on those resolutions at his/her/their discretion**; and

(b) in respect of Resolution 16, for which cumulative voting will apply, he/she/it must give specific instructions as to how many votes he/she/it wishes to cast on Resolution 16, in the Proxy Form. **If no specific direction as to how many votes is given, the proxy(ies) may vote or abstain from voting on Resolution 16 at his/her/their discretion.**

The Proxy Form has been made available via SGXNet and may also be accessed at the Company's website at www.jydrt.com.cn.

Investors who hold Shares under the CPF ("**CPF Investor**") and/or the SRS ("**SRS Investor**") (as may be applicable) and wish to vote should inform their respective CPF Agent Banks and/or SRS Operators to submit their votes at least **seven (7)** working days before the date of the AGM (i.e. by **5:00 p.m.** on **Tuesday, 5 May 2026**). **The Proxy Form is not valid for use by CPF Investors and SRS Investors and shall be ineffective for all intents and purposes if used or purported to be used by them.**

The duly completed Proxy Form must be submitted by S-Share Shareholders to the Company in the following manner:

(a) if submitted by post, be lodged with the Company's S-Shares Registrar and Singapore Transfer Office, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, Keppel Bay Tower #14-07, Singapore 098632; or

(b) if submitted electronically, via email to the Company's S-Shares Registrar and Singapore Transfer Office at srs.proxy@boardroomlimited.com,

in either case, by no later than **1:30 p.m.** on **Wednesday**, **13 May 2026**.

S-Share Shareholders are strongly encouraged to submit completed Proxy Forms electronically via email.

A S-Share Shareholder who wishes to submit an instrument of proxy must first complete and sign the Proxy Form, before submitting it by post to the address provided above, or before scanning and sending it by email to the email address provided above. If a S-Share Shareholder is a corporation, the Proxy Form must be executed under seal or by the hand of its duly authorised officer or attorney.

The completion and return of the instrument appointing a proxy(ies) by a Shareholder do not preclude such Shareholder from attending, speaking and voting in person at the AGM if such Shareholder subsequently decides to do so. The appointment of the proxy(ies) for the AGM will be deemed to be revoked if the Shareholder attends the AGM in person and in such event, the Company reserves the right to refuse to admit any person or persons appointed under the relevant instrument appointing a proxy(ies) to the AGM.

5. Pursuant to the Articles of Association of the Company, a holder of tradable domestic A-Shares with limiting conditions for sale shall notify the Company in writing not less than twenty (20) days prior to the AGM of his or her intention to attend the AGM. Accordingly, a holder of tradable domestic A-Shares with limiting conditions for sale who is planning to attend the AGM must give a written notice to the Company no later than 21 April 2026.

6. The AGM in Tianjin, the PRC is expected to last for half a day and all accommodation and other expenses incurred by a Shareholder or his/her/its proxy(ies) in connection with his/her/its attendance at the AGM shall be borne by that Shareholder.

7. **Personal data privacy**: By (1) submitting a proxy form appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the AGM and/or any adjournment thereof, and/or (2) submitting any question prior to the AGM, a Shareholder of the Company (a) consents to the collection, use and disclosure of the Shareholder's personal data by the Company (or its agents or service providers) for the purposes of (i) the processing and administration by the Company (or its agents or service providers) of proxies and representatives appointed for the AGM (including any adjournment thereof), (ii) the preparation and compilation of the attendance lists, minutes and other documents relating to the AGM (including any adjournment thereof), (iii) the addressing of substantial and relevant questions relating to the resolution(s) to be tabled for approval at the AGM from Shareholders received prior to and/or at the AGM and if necessary, the follow-up with Shareholders in relation to such questions, and (iv) in order for the Company (or its agents or service providers) to comply with any applicable laws, listing rules, regulations and/or guidelines (collectively, the "**Purposes**"); (b) warrants that where a Shareholder discloses the personal data of such Shareholder's proxy(ies) and/or representative(s) to the Company (or its agents or service providers), such Shareholder has obtained the prior consent of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents or service providers) of the personal data of such proxy(ies) and/or representative(s) for the Purposes; and (c) agrees that the Shareholder will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the Shareholder's breach of warranty.